Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Purple Biotech ( (PPBT) ).
On September 19, 2025, Purple Biotech Ltd. entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, allowing the company to offer and sell ADSs through Wainwright as an agent. This agreement enables the company to raise up to $2.3 million, potentially impacting its financial operations and market positioning. Additionally, on September 18, 2025, the company terminated its previous ATM agreement with Jefferies LLC, under which it had sold 983,317 ADSs for gross proceeds of $7.7 million since June 2021.
The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Underperform.
Purple Biotech’s overall stock score reflects significant financial challenges and unattractive valuation metrics. The absence of revenue and ongoing losses weigh heavily on financial performance. Technical indicators are mixed, with some potential downside risks. The lack of profitability and dividends further contribute to a low valuation score.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech Ltd. is a company based in Israel, operating in the biotechnology industry. The company primarily focuses on developing innovative therapeutics and is involved in the market for American Depositary Shares (ADSs), which represent its ordinary shares.
Average Trading Volume: 1,018,131
Technical Sentiment Signal: Sell
Current Market Cap: $5.94M
For a thorough assessment of PPBT stock, go to TipRanks’ Stock Analysis page.